NCNA - יחס מהיר NuCana PLC

The price trajectory for NuCana plc (NCNA) shown below is based on the 4.82 metric. The biotech's financial stability depends on clinical trial outcomes, although its patent portfolio mitigates the risks associated with a narrow development profile. The business remains vulnerable to European instability and component supply chain disruptions. Growth is driven by the success of ProTide technology and the creation of less toxic nucleoside analogs for tumor treatment.

The quick ratio assesses the ability of NuCana plc (NCNA) to settle short-term debts using cash and accounts receivable, completely excluding low-liquidity inventory. This calculation is critical for NuCana plc, as its stable British legal status and humanitarian business profile minimize external financial shocks. By analyzing the liquidity check via the acid test, an investor can see the real capital cushion. High indicators confirm the biotech's resilience.